| Original language | English (US) |
|---|---|
| Pages (from-to) | 2762-2766 |
| Number of pages | 5 |
| Journal | Leukemia |
| Volume | 33 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 1 2019 |
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Leukemia, Vol. 33, No. 11, 01.11.2019, p. 2762-2766.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma
AU - Wang, Michael
AU - Rule, Simon
AU - Zinzani, Pier Luigi
AU - Goy, Andre
AU - Casasnovas, Olivier
AU - Smith, Stephen D.
AU - Damaj, Gandhi
AU - Doorduijn, Jeanette K.
AU - Lamy, Thierry
AU - Morschhauser, Franck
AU - Panizo, Carlos
AU - Shah, Bijal
AU - Davies, Andrew
AU - Eek, Richard
AU - Dupuis, Jehan
AU - Jacobsen, Eric
AU - Kater, Arnon P.
AU - Le Gouill, Steven
AU - Oberic, Lucie
AU - Robak, Tadeusz
AU - Jain, Preetesh
AU - Frigault, Melanie M.
AU - Izumi, Raquel
AU - Nguyen, Dorothy
AU - Patel, Priti
AU - Yin, Ming
AU - Długosz-Danecka, Monika
N1 - Funding Information: Acknowledgements This study was sponsored by Acerta Pharma, a member of the AstraZeneca Group. We thank the patients who participated in this trial and their families and caregivers; the investigators and coordinators at each study site; and the Acerta Pharma study team, including Sofia Wong. Medical writing assistance was provided by Stephanie Morgan of Team9Science and funded by Acerta Pharma. Funding Information: Conflict of interest MW is a consultant for AstraZeneca, Janssen, and MoreHealth, has received honoraria from Acerta Pharma, Celgene, Dava Oncology, Janssen, and Pharmacyclics, has received research funding from Acerta Pharma, AstraZeneca, Celgene, Janssen, Kite Pharma, Juno, Novartis, and Pharmacyclics, and is a member of the Board of Directors or advisory committees for Celgene and Janssen. SR is a consultant for, a member of the Board of Directors or advisory committees for, and has received honoraria from AstraZeneca, Celgene, Celltrion, Gilead, Janssen, Kite, and Roche, has received research funding from Janssen, and participates in a speakers’ bureau for Celgene. PLZ has received honoraria from BMS, Celgene, Celltrion, Gilead, Janssen, MSD, Roche, and Servier, and participates in a speakers’ bureau for AstraZeneca, BMS, Gilead, Janssen, MSD, Servier, and Verastem. AG is a consultant for Acerta Pharma, Celgene, Kite/Gilead, Pharmacyclics/J&J, and Takeda, has received honoraria from Celgene, Pharmacyclics/J&J, and Takeda, is a member of the Board of Directors or advisory committees for Acerta Pharma, Celgene, COTA, Kite/Gilead, Pharmacyclics/J&J, and Takeda, has received research funding from Acerta Pharma, Celgene, Genentech, Kite/Gilead, Pharmacyclics/J&J, and Seattle Genetics, and participates in a speakers bureau for Acerta Pharma, Celgene, Pharmacyclics/J&J, and Takeda. OC is a consultant for Gilead, Janssen, Merck, MSD, Roche, and Takeda, has received honoraria from Celgene, Gilead, Janssen, Merck, MSD, Roche, and Takeda, and has received research funding from Gilead and Roche. SDS is a consultant for Merck Sharpe Dohme and Corp, and has received research funding from Acerta Pharma, Genentech, Merck Sharpe Dohme and Corp, Pharmacyclics, Portola, and Seattle Genetics. FM is a consultant for Celgene and Gilead, is a member of the Board of Directors or advisory committees for BMS, Celgene, Gilead, and Roche, and gives scientific lectures for Janssen and Roche. CP is a consultant for Roche, participates in a speakers’ bureau for Celgene, Janssen, and Roche, has received research funding from Acerta Pharma, is a member of the Board of Directors or advisory committees for BMS and Janssen. AD is a consultant for Acerta Pharma, Celgene, Janssen, Karyopharma, Kite, Roche, and Takeda, and has received research funding from Acerta Pharma, Celgene, Gilead, GSK, Karyopharma, Pfizer, and Roche. BS reports relationships with Amgen, Incyte, and Pharmacyclics that do not exceed $5000, nor are relevant to this content. RE is a member of the Ramsay Hospital Medical Advisory Committee. EJ is a consultant for AstraZeneca, Merck, and Seattle Genetics. APK has received honoraria from Abbie, Genentech, and Janssen, and research funding from Abbie, Acerta/AstraZeneca, Genentech, and Janssen. LO is a consultant for Janssen, Sanofi, and Takeda, and has received honoraria from Janssen. TR has received research funding from Acerta Pharma. DN, MY, and PP are employees of Acerta Pharma and have equity ownership of Acerta and AstraZeneca. RI is an employee of, has equity ownership of and patents at Acerta Pharma, and has equity ownership of AstraZeneca. MMF is an employee of and has equity ownership and patents at AstraZeneca. MDD is a consultant for Janssen, Roche, Servier and Takeda, and gives scientific lectures for Janssen, Servier, and Roche. GD, JD, JKD, SL, and TL declare no competing interests.
PY - 2019/11/1
Y1 - 2019/11/1
UR - http://www.scopus.com/inward/record.url?scp=85074001569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074001569&partnerID=8YFLogxK
U2 - 10.1038/s41375-019-0575-9
DO - 10.1038/s41375-019-0575-9
M3 - Letter
C2 - 31558766
AN - SCOPUS:85074001569
SN - 0887-6924
VL - 33
SP - 2762
EP - 2766
JO - Leukemia
JF - Leukemia
IS - 11
ER -